At Iovance Biotherapeutics, I serve as Lead CDM for TILVANCE-301, a pivotal Phase 3 study of lifileucel TIL cell therapy, overseeing data management across 100+ global investigative sites. I also manage data operations for two Phase 2 oncology studies and lead CRF design and database builds in Medidata Rave.
Previously, I managed Phase 1–3 studies at Syneos Health across neuroscience, immunology, and cardiovascular conditions, and supported clinical data management at Johnson & Johnson. My work includes EDC administration, CDISC/CDASH standards, safety reconciliation, and regulatory-ready data deliverables; I have 8 years of experience across these therapeutic areas.
